Medtronic Shares Dip Amid $650M SPR Therapeutics Acquisition

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2026-05-20 19:54:02

BTCCSquare news:

Medtronic's stock fell 1.44% to $77.45 following the announcement of its $650 million all-cash acquisition of SPR Therapeutics. The deal aims to bolster Medtronic's neuromodulation portfolio, particularly in minimally invasive pain management.

SPR's FDA-cleared SPRINT PNS System offers 60-day temporary pain relief without permanent implants, aligning with Medtronic's strategy to expand chronic pain treatment options. The therapy could address nearly 50 million U.S. adults suffering from chronic pain.

The acquisition reflects Medtronic's continued focus on strengthening core franchises through strategic purchases. Market reaction suggests investor caution despite the long-term growth potential in neuromodulation therapies.

By:

Log in to Reply

South Carolina Enacts Sweeping Crypto Protections While Blocking CBDCs

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.